- New Consensus Sees Stimulus Package as Worthy Step
- Black Friday Deals May Not Signal Retail Comeback
- Thanksgiving Week Stuffed With Economic News
- UPS Sets New Rates For 2010
- Wall Street Jobs Slow to Return Despite Record Profits
- Investors to Goldman: Be Less Greedy
- Victoria's Secret Hopes to Rekindle Desire for Lingerie
- Senate Panel to Mull Bernanke Nomination On Dec. 3
- $6M Verdict Upheld in McDonald's Strip Search Case
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Deep Discounts Should Make It a Very Tech-y Holiday
MOST SHARED
Text Size 
GlaxoSmithKline has won U.S. marketing approval to sell an unadjuvanted H1N1 swine vaccine, allowing it to ship relatively modest amounts of scarce vaccine to the United States next month.
The British company said on Tuesday the Food and Drug Administration had approved a modified version of its FluLaval seasonal flu vaccine containing the new H1N1 strain.
The green light clears the way for it to fill a order for 7.6 million doses from the U.S. government.
Glaxo [GSK-LN Loading... ()] is one of the world's largest manufacturers of flu vaccines, along with Sanofi-Aventis and Novartis.
But it is not a big source of swine flu vaccine for the United States, since its main H1N1 vaccine Pandemrix contains an adjuvant, or additive, and is not being used here.
The company's chief executive, Andrew Witty, told reporters last month that it would be only a "bit-part player in the U.S. flu scenario."
The 7.6 million doses of Glaxo's unadjuvanted vaccine, which is being manufactured in Canada, is just a small fraction of the 250 million doses ordered by the U.S. government.
Glaxo said it expected to start shipping its vaccine in December and complete deliveries by the end of the year.
Worldwide, Glaxo has taken orders for more than 440 million doses of its adjuvanted Pandemrix H1N1 vacccine.
- Technology can make or break a fortune in the world of alternative energy.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- From salt, to lip balm to envelopes, it turns out that bacon flavoring can sell almost anything.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes